Author: admin
-
What we learned from the ISU Grand Prix Final 2025
Which women will emerge from Japan?
Surging 17-year-old Nakai Ami won silver in her Grand Prix Final debut, amid her rookie senior season. Three-time world champion Sakamoto Kaori bounced back from a forgettable short program to secure bronze,…
Continue Reading
-
KLEVV CRAS V RGB 48 GB DDR5-9600 CL36 Memory Review: Extremely Fast!
Product Info KLEVV CRAS V RGB DDR5 9600 48 GB
December, 2025
Type
Memory Kit
Price
TBD
The DDR5 memory segment has been experiencing significant activity as it becomes standardized across all…
Continue Reading
-
The Targeted Pulse: FDA Approvals, Trial Updates, and ASH 2025 Previews | Targeted Oncology
Welcome to this week’s edition of The Targeted Pulse, your weekly wrap-up of the top developments in oncology. This week, we saw FDA decisions, learned about care-changing trial data, and got a preview of the most anticipated 67th American Society of Hematology (ASH) Annual Meeting and Expositionabstracts. From regulatory designations for promising new drugs to crucial clinical trials, here are the top stories that shaped the week.
The FDA has granted premarket approval to the IsoPSA blood-based in vitro diagnostic kit, intended to aid clinicians in deciding whether to proceed with prostate biopsy. It is indicated for men aged ≥ 50 years with elevated prostate-specific antigen (PSA) levels.
Unlike traditional PSA testing, IsoPSA leverages the IsoClear™ platform to analyze structural characteristics (isoforms) of the PSA protein, offering enhanced specificity. Clinical utility is recognized by inclusion in NCCN and AUA/SUO guidelines, as it improves risk stratification for high-grade (Gleason score ≥7) prostate cancer. The test is expected to decrease unnecessary biopsies stemming from benign PSA elevations.
The phase 3 OptiTROP-Lung05 trial demonstrated that the combination of sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate [ADC], plus pembrolizumab (Keytruda) offers a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab monotherapy for first-line treatment of advanced, PD-L1-positive non–small cell lung cancer (NSCLC).
This study marks the first time an ADC combined with an immune checkpoint inhibitor has met a primary end point in the first-line NSCLC setting. The regimen also showed a positive trend in overall survival (OS) with a manageable safety profile. This combination represents a new, highly effective, and novel therapeutic option for clinicians managing these patients.
The FDA has granted traditional approval to pirtobrutinib (Jaypirca), a highly selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor, for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This indication specifically targets patients previously treated with a covalent BTK inhibitor.
The decision is based on the phase 3 BRUIN-CLL-321 trial, which showed a statistically and clinically significant PFS benefit. Median PFS was 11.2 months (95% CI, 9.5–11.4) with pirtobrutinib vs 8.7 months (95% CI, 7.2–10.2) for investigator’s choice of therapy (HR, 0.58; P =.0105). This noncovalent agent provides a mechanism to continue BTK pathway targeting after resistance to covalent inhibitors.
The Targeted Oncology® poll highlighted several practice-changing abstracts for the 67th ASH Annual Meeting and Exposition, primarily in multiple myeloma (MM), CLL, and myelofibrosis. The most anticipated presentation is the phase 3 MajesTEC-3 trial, which evaluated the combination of the bispecific antibody teclistamab plus daratumumab (Tec-Dara) against standard-of-care regimens in relapsed/refractory MM. The data demonstrated statistically and clinically significant improvements in PFS and OS for Tec-Dara. These findings support establishing the Tec-Dara regimen as a new standard of care early in the R/R MM treatment landscape. Other highly anticipated data include primary results for pirtobrutinib in previously untreated CLL/SLL (LBA-3).
The bispecific HER2-directed ADC TQB2102 demonstrated robust activity in the phase 2 TQB2102-II-01 trial as a neoadjuvant therapy for HER2-positive breast cancer. Its novel design targets 2 non-overlapping HER2 epitopes to enhance blockade.
The 6.0 mg/kg regimen administered over 8 cycles achieved the highest total pathologic complete response rate at 76.9% (90% CI, 62.3%–87.6%). The drug exhibited a favorable safety profile, with grade 3 treatment-related adverse events occurring in 27.9% of patients across all cohorts. These compelling efficacy and safety data support the ongoing randomized phase 3 evaluation of TQB2102 against standard neoadjuvant regimens in this patient population.
Continue Reading
-
Is USA Rare Earth’s 2025 Valuation Justified After 49.9% Gain and Policy Driven Hype?
-
Wondering if USA Rare Earth is actually worth the hype at its current price, or if the story has already run ahead of the fundamentals? This breakdown is designed to give you a clear, valuation focused view.
-
USA Rare Earth has been anything but quiet lately, jumping 28.0% over the last week and climbing 39.2% year to date. This is even though the 30 day move is roughly flat at -0.8% and the 1 year gain sits at 49.9%.
-
Much of that momentum has been fueled by ongoing headlines around US efforts to secure domestic supplies of critical minerals and reduce dependence on overseas rare earth processing. As USA Rare Earth positions itself as part of that strategic supply chain, investors are starting to price in the potential upside and the risks that come with policy driven demand.
-
Right now, USA Rare Earth scores a 2/6 valuation check score. This means it screens as undervalued on 2 of our 6 metrics, and in the next sections we will unpack those traditional valuation approaches before finishing with a more holistic way to judge whether the current price really makes sense.
USA Rare Earth scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
A Discounted Cash Flow (DCF) model estimates what a business is worth today by projecting its future cash flows and discounting them back to their present value. For USA Rare Earth, this uses a 2 Stage Free Cash Flow to Equity framework.
The company is currently burning cash, with last twelve month free cash flow at around -$39.0 Million. Analyst forecasts and subsequent extrapolations see this negative cash flow deepening to roughly -$114.4 Million in 2026 before turning positive and climbing to about $438.5 Million by 2035. These later years rely on Simply Wall St extrapolations once analyst coverage runs out.
When all those projected cash flows are discounted back, the model arrives at an intrinsic value of about $40.05 per share. Compared with the current share price, this implies the stock is trading at roughly a 57.0% discount, suggesting the market is heavily discounting the long term cash flow recovery story.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests USA Rare Earth is undervalued by 57.0%. Track this in your watchlist or portfolio, or discover 907 more undervalued stocks based on cash flows.
USAR Discounted Cash Flow as at Dec 2025 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for USA Rare Earth.
For asset heavy businesses in the metals and mining space, the price to book ratio is often a useful reality check because it compares what investors are paying in the market with the accounting value of the company’s net assets. In theory, faster growth and lower risk justify a higher multiple, while slower growth or higher uncertainty should pull a fair price to book closer to, or even below, the value of the underlying assets.
Continue Reading
-
-
Sydney Sweeney says her silence over jeans advert backlash ‘widened the divide’ | Sydney Sweeney
The actor Sydney Sweeney has said she should have addressed the controversy surrounding her American Eagle jeans advert, which was accused by critics of flirting with eugenics, saying not doing so “widened the divide” between people.
Sweeney,…
Continue Reading
-
Grim Signals of Future Antimicrobial Resistance Found Lurking in Sewage : ScienceAlert
Dangerous bacteria and other disease-causing microbes are rapidly evolving ways to defy our best antibiotic medications, a phenomenon known as antimicrobial resistance. Humans are inadvertently contributing by overexposing pathogens to our…
Continue Reading
-
Company linked to raid on illicit weight-loss drug facility still selling unlicenced drugs | Consumer affairs
The company linked to the largest global raid on an illicit weight-loss drug facility is still selling unlicenced drugs to thousands of customers, a Guardian investigation has found.
Just over a month after the Medicines and Healthcare products Regulatory Agency (MHRA) raided the site and released images of seized products with the Alluvi brand name visible, the company is still selling replicas of retatrutide. It is understood that nobody has yet been arrested in connection to the raid.
Retatrutide, which has not yet completed clinical trials, is an experimental injection developed by the US drugmaker Eli Lilly that targets three gut hormones: GLP-1, GIP and glucagon. Because it remains in clinical trials and is not approved for use, any sale to consumers is illegal. Despite this, counterfeit versions are being widely promoted on social media, with Alluvi – which did not respond to a request for comment – emerging as a key seller.
The MHRA seized unlicensed medication said to be worth £250,000 in its October raid. Photograph: MHRA/PA During the October raid, the MHRA carried out one of the largest single seizures of trafficked weight-loss drugs ever recorded globally. Officers confiscated tens of thousands of empty pens ready to be filled, raw chemical ingredients, and more than 2,000 unlicensed retatrutide and tirzepatide branded Alluvi pens destined for customers.
They also found large quantities of sophisticated packaging and manufacturing equipment, along with about £20,000 in cash suspected to be linked to medicines trafficking.
Despite this, Alluvi Healthcare Limited continues sales on multiple Telegram channels, one of which has nearly 3,000 subscribers. On 27 October, shortly after news of the raid emerged, one of its channels showed Alluvi-branded retatrutide pens, stating, “we are still fully in stock via telegram”.
Alluvi’s website is also still up and running as of 5 December, selling a “retatrutide 40mg x2 Bundle (R&D Only) for £339.99”. It advises customers: “If you’re using retatrutide for the first time, it’s essential to follow a gradual dosing plan to allow your body to adjust and minimise side effects.”
Buying retatrutide illegally carries serious risks. Because the drug is still experimental, products sold online or through unofficial channels are unregulated and may not contain the correct ingredients or dosage, and may not be sterilised to the correct standard.
Contaminated or incorrectly dosed injectable hormones can cause infections, dangerous blood sugar crashes, pancreatitis and cardiovascular side-effects. Using an unfinished clinical-trial drug outside legitimate medical settings is unsafe and potentially life-threatening.
One person who bought the Alluvi pen told the Guardian, speaking anonymously, that they had experienced severe “gastrointestinal issues, unstable peaks and troughs of energy, and dehydration”.
One of Alluvi’s Telegram channels also shares a video claiming to show a Royal Mail employee assuring buyers that “orders will be scanned in and they will be out for delivery”, and prompting the worker to say “from Alluvi”. The post promised next-day delivery.
On 1 December, the same account advertised that its “pens [are] in stock”, offering a 25% discount and directing customers to another Telegram channel for payments. Another Telegram channel – with over 2,000 members – includes a plethora of customers talking about their experiences taking the counterfeit weight-loss drugs.
The Guardian has seen evidence suggesting that payments for Alluvi products are being processed by an e-commerce business called Nutri Collectiv. Screenshots of orders indicate that customers buy what is described as a “weight loss plan”, with payments routed through Stripe, allowing the transactions to masquerade as fitness-programme purchases and avoid detection.
The MHRA seized counterfeit syringes of weight-loss medication in the raid. Photograph: MHRA A Channel 4 investigation found that individuals who spoke negatively about Alluvi had their social media accounts taken over. Two TikTok accounts with millions of followers were used to impersonate legitimate weight-loss influencers who had criticised fake weight-loss drugs. The operators cloned the influencers’ profiles by copying their names and profile pictures, then contacted TikTok claiming to be the real account holders and alleging impersonation.
TikTok subsequently shut down the legitimate accounts, leaving the fake ones active. Five weight-loss affiliates told Channel 4 they had lost their TikTok accounts in this way.
Concerns about illicit production models of weight-loss drugs are heightened during the winter months, as it becomes harder to know whether products have been stored correctly.
Experts warn that colder temperatures can pose risks when it comes to storing weight-loss injections. Jason Murphy, a weight-loss expert and head of pharmacy at Chemist4U, said that winter temperatures can affect storage conditions and that the effectiveness and safety of the drug could be compromised.
“These drugs are made from living organisms and are highly sensitive to temperature variations and extreme highs or lows,” he added. “Extremely cold temperatures or freezing can damage their protein structure, reduce their medicinal effect, and potentially make them unsafe to use even after thawing … If you believe your weight-loss injection has been frozen, dispose of it immediately.”
The MHRA declined to comment.
sarah.marsh@theguardian.com
Continue Reading
-
iPhone 17 Pro Loses Fight Against the Oppo Find X9 Pro’s Camera
The iPhone 17 Pro is unquestionably among the best camera systems available. It can take amazing images in all sorts of conditions with almost no effort on your part. But there are a number of top-end Android phones that pack serious photography…
Continue Reading
